|  |
| --- |
| **Supplemental Table 1. Trends in oral systemic and phototherapy for psoriasis.** |
| **Drug** | **Year** | **Type of visit** | **Insurance** | **Metropolitan** | **PsA** |
| **All**  | **Dermatology** | **Non-Dermatology** | **Public** | **Private** | **Yes** | **No** | **Yes** | **No** |
| Oral Immunosuppressants | 2001-2005 | 4.4% (1.5%-7.2%) | 3.9% (1.1%-6.8%) | 5.2% (0.0%-10.5%) | 5.5% (0.8%-10.1%) | 3.7% (0.3%-7.1%) | 4.5% (1.5%-7.6%) | 2.4% (0.0%-7.2%) | 26.2% (0.0%-48.4%) | 4.2% (1.3%-7.0%) |
| 2006-2010 | 4.7% (2.3%-7.0%) | 5.9% (2.7%-9.1%) | 2.3% (0.0%-5.4%) | 7.9% (1.7%-14.1%) | 3.0% (0.8%-5.3%) | 4.5% (1.9%-7.2%) | 5.2% (0.0%-10.3%) | 34.5% (18.7%-50.3%) | 4.7% (2.3%-7.2%) |
| 2011-2015 | 6.0% (3.6%-8.4%) | 6.6% (3.4%-9.8%) | 5.2% (1.5%-8.8%) | 3.5% (0.4%-6.6%) | 5.9% (2.9%-8.8%) | 6.3% (3.8%-8.8%) | 0.9% (0.0%-2.7%) | 16.7% (6.7%-26.7%) | 5.5% (3.3%-7.8%) |
| *Cyclosporine* | 2001-2005 | 0.5%(0.0%-1.9%) | 0.8% (0.0%-1.9%) | 0% | 1.4% (0.0%-4.0%) | 0.2% (0.0%-0.7%) | 0.5% (0.0%-1.3%) | 0% | 0% | 0.5% (0.0%-1.2%) |
| 2006-2010 | 1.2% (0.1%-2.3%) | 1.2% (0.1%-2.3%) | 0% | 1.9% (0.0%-4.5%) | 0% | 0.8% (0.0%-1.6%) | 0.8% (0.0%-2.2%) | 0% | 0.8% (0.0%-1.6%) |
| 2011-2015 | 1.0% (0.0%-2.2%) | 1.0% (0.0%-2.2%) | 0.3% (0.0%-0.8%) | 0% | 1.0% (0.0%-2.2%) | 0.7% (0.0%-1.5%) | 0% | 0% | 0.7% (0.0%-1.4%) |
| *Methotrexate* | 2001-2005 | 3.9% (1.1%-6.6%) | 3.2% (0.6%-5.8%) | 5.2% (0.0%-10.5%) | 4.1% (0.4%-7.9%) | 3.5% (0.1%-6.8%) | 4.0% (1.1%-6.9%) | 2.4% (0.0%-7.2%) | 26.2% (0.0%-48.4%) | 3.7% (0.9%-6.4%) |
| 2006-2010 | 3.9% (1.7%-6.0%) | 4.7% (1.8%-7.6%) | 2.3% (0.0%-5.4%) | 6.0% (0.3%-11.7%) | 3.0% (0.8%-5.3%) | 3.8% (1.3%-6.2%) | 4.4% (0.0%-9.0%) | 34.5% (18.7%-50.3%) | 4.0% (1.7%-6.2%) |
| 2011-2015 | 5.3% (3.0%-7.5%) | 6.0% (3.0%-9.0%) | 4.3% (0.9%-7.7%) | 3.3% (0.3%-6.2%) | 4.8% (2.0%-7.6%) | 5.5% (3.1%-7.9%) | 0.9% (0.0%-2.7%) | 16.7% (6.7%-26.7%) | 4.7% (2.6%-6.8%) |
| SCS | 2001-2005 | 1.6% (0.0%-3.3%) | 0.5% (0.0%-1.2%) | 3.5% (0.0%-8.6%) | 0.6% (0.0%-1.7%) | 2.1% (0.0%-4.7%) | 1.7% (0.0%-3.6%) | 0 | 1.6% (0.0%-3.3%) | 1.6% (0.0%-3.3%) |
| 2006-2010 | 3.4% (1.0%-5.8%) | 1.6% (0.0%-3.3%) | 6.9% (0.8%-13.1%) | 7.9% (0.2%-15.6%) | 2.0% (0.1%-3.9%) | 3.1% (0.4%-5.8%) | 4.7% (0.0%-9.7%) | 3.3% (0.9%-5.7%) | 3.3% (0.9%-5.7%) |
| 2011-2015 | 5.5% (2.6%-8.5%) | 0.8% (0.0%-1.9%) | 11.6% (5.4%-17.8%) | 5.9% (0.0%-12.0%) | 5.3% (1.8%-8.7%) | 5.6% (2.5%-8.7%) | 4.5% (0.0%-9.8%) | 5.1% (2.2%-7.9%) | 5.1% (2.2%-7.9%) |
| *Prednisolone* | 2001-2005 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2006-2010 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2011-2015 | 0.6% (0.1%-2.2%) | 0% | 1.3% (0.3%-5.1%) | 1.1% (0.2%-7.5%) | 0.4% (0.1%-2.5%) | 0.6% (0.2%-2.3%) | 0% | 0.1% (0.0%-0.3%) | 0.6% (0.1%-2.3%) |
| *Methylprednisolone* | 2001-2005 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2.8% (2.1%-3.6%) | 0% |
| 2006-2010 | 1.9% (0.7%-5.2%) | 0.4% (0.1%-3.1%) | 4.8% (1.5%-14.1%) | 4.4% (1.0%-16.8%) | 1.2% (0.3%-4.2%) | 2.1% (0.7%-6.2%) | 1.1% (0.1%-7.5%) | 0.9% (0.7%-1.1%) | 1.8% (0.6%-5.2%) |
| 2011-2015 | 3.1% (1.5%-6.3%) | 0.4% (0.1%-2.8%) | 6.6% (3.1%-13.6%) | 2.7% (0.6%-11.1%) | 3.5% (1.5%-8.1%) | 3.2% (1.5%-6.6%) | 1.7% (0.2%-11.3%) | 6.0% (1.9%-10.2%) | 2.6% (1.2%-5.5%) |
| *Prednisone* | 2001-2005 | 1.6% (0.0%-3.3%) | 0.5% (0.0%-1.2%) | 2.6% (0.0%-8.6%) | 0.6% (0.05%-1.7%) | 2.1% (0.0%-4.7%) | 1.7% (0.0%-3.6%) | 0.0% | 3.5% (0.0%-11.0%) | 1.6% (0.0%-3.3%) |
| 2006-2010 | 1.5% (0.0%-2.9%) | 1.1% (0.0%-2.7%) | 2.1% (0.0%-5.2%) | 3.5% (0.0%-8.2%) | 0.9% (0.0%-2.1%) | 1.0% (0.0%-2.4%) | 3.6% (0.0%-8.2%) | 6.0% (0.0%-15.7%) | 1.5% (0.0%-3.0%) |
| 2011-2015 | 1.8% (0.3%-3.2%) | 0.4% (0.0%-1.1%) | 3.5% (0.4%-6.7%) | 0.5% (0.0%-1.2%) | 2.0% (0.0%-4.1%) | 1.7% (0.2%-3.3%) | 2.1% (0.0%-6.9%) | 8.0% (0.9%-15.1%) | 1.8% (0.3%-3.3%) |
| Phototherapy | 2001-2005 | 3.8% (1.1%-6.4%) | 5.8% (2.0%-9.6%) | 0% | 7.1% (0.3%-13.8%) | 2.7% (0.0%-5.7%) | 3.6% (0.8%-6.4%) | 5.6% (0.0%-12.3%) | 0% | 3.8% (1.2%-6.4%) |
| 2006-2010 | 2.9% (1.0%-4.7%) | 3.4% (1.2%-5.6%) | 1.9% (0.0%-5.1%) | 0% | 3.9% (1.3%-6.5%) | 2.5% (0.6%-4.5%) | 4.4% (0.0%-10.3%) |  | 2.9%(1.0%-4.8%) |
| 2011-2015 | 3.3% (1.3%-5.4%) | 5.5% (2.1%-8.9%) | 0.5% (0.0%-1.6%) | 2.4% (0.0%-5.2%) | 3.1% (1.0%-5.3%) | 3.5% (1.3%-5.7%) | 0% | 0% | 3.5% (1.3%-5.6%) |
| Oral Acitretin | 2001-2005 | 4.5% (1.9%-7.0%) | 5.6% (2.7%-8.4%) | 2.4% (0.0%-7.1%) | 3.8% (0.0%-7.7%) | 4.2% (0.9%-7.5%) | 4.6% (1.8%-7.3%) | 3.2% (0.0%-8.6%) | 0% | 4.5% (1.9%-7.0%) |
| 2006-2010 | 2.3% (0.0%-4.7%) | 3.1% (0.0%-6.6%) | 0.7% (0.0%-2.2%) | 1.2% (0.0%-3.3%) | 2.7% (0.0%-6.2%) | 2.7% (0.0%-5.5%) | 0.8% (0.0%-2.2%) | 0% | 2.4% (0.0%-4.8%) |
| 2011-2015 | 1.7% (0.3%-3.0%) | 3.0% (0.6%-5.4%) | 0% | 0.3% (0.0%-0.8%) | 2.2% (0.2%-4.2%) | 1.8% (0.4%-3.2%) | 0.0% | 5.7% (0.0%-16.9%) | 1.5% (0.2%-2.9%) |

 Weighted prevalence and 95% confidence intervals (CI) are presented for systemic agents among patients with a diagnosis of psoriasis. Systemic agents include oral immunosuppressants (cyclosporine or methotrexate), systemic corticosteroids (SCS; prednisone, methylprednisolone, and prednisolone), and acitretin. Results are stratified by dermatology/non-dermatology, public/private insurance, metropolitan/non-metropolitan, and PsA/no PsA